In a strategic move poised to reshape the landscape of obesity treatment, Roche Holding AG has announced a landmark collaboration with Denmark’s Zealand Pharma. The partnership centers on the development and commercialization of petrelintide, an innovative amylin analog, marking Roche’s ambitious entry into the burgeoning weight-loss market.
A Landmark Agreement
The collaboration, unveiled on March 12, 2025, entails Roche making an upfront payment of $1.65 billion to Zealand Pharma, with the potential for additional milestone payments that could bring the total value to $5.3 billion. This agreement grants Roche co-development and co-commercialization rights to petrelintide,
